Issues in the assessment of non-inferiority: Perspectives drawn from case studies

Pharmaceutical Statistics

Volumn 10, Issue 5, 2011, Pages 433-439

  Burger, H Ulrich ^a   Beyer, Ulrich ^a   Abt, Markus ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

assay sensitivity; constancy assumption; effect retention; non inferiority; time to event

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO;

ADVERSE OUTCOME; ANEMIA; ARTICLE; CASE STUDY; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; COLORECTAL CANCER; DRUG SAFETY; EXPERIMENTAL STUDY; HUMAN; KIDNEY DISEASE; METHODOLOGY; PLACEBO EFFECT; STANDARD; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; CONTROL GROUPS; DIALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; EVALUATION STUDIES AS TOPIC; HUMANS; KIDNEY DISEASES; MODELS, STATISTICAL; PATIENT SATISFACTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 80053560929     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.512     Document Type: Article

References (10)

1. Snapinn S,. Non-inferiority trials. Current Controlled Trials in Cardiovascular Medicine 2000; 1: 19-21.
2. Rothmann M, Li N, Chen G, Chi GYH, Temple RT, Tsou HH,. Non-inferiority methods for mortality trials. Statistics in Medicine 2003; 22: 239-264.
3. FDA guidance. Guidance for industry Non-inferiority Clinical trials, Draft guideline, FDA, 2010. Available on.
4. Snapinn SM, Jiang Q,. Controlling the type I error rate in non-inferiority trials. Statistics in Medicine 2008; 27: 371-381. (Pubitemid 351227873)
5. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of clinical oncology 2008; 26 (12): 2006-2012.
6. Zori CA, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. European Journal of Cancer 2001; 37: 1006-1013.
7. Rothenberg ML, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proceeding of the American Society of Clinical Oncology 2003; 22. (abstract 1011, presentation slides).
8. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000; 18 (16): 2938-47. (Pubitemid 30644117)
9. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proceeding of the American Society of Clinical Oncology 2002; 21: 129a. abstract 512 (oral presentation slides).
10. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Journal of the American Society Nephrology 2008; 28: 280-289.